CHF 6297

Drug Profile

CHF 6297

Alternative Names: CHF-6297; CHI-91040; MAPK14 inhibitor

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Chiesi Farmaceutici
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic obstructive pulmonary disease

Most Recent Events

  • 18 May 2018 Pharmacodynamics data from preclinical studies presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 18 Jul 2017 Chiesi Farmaceutici suspends patient enrolment for precaution due to safety issues in preclinical studies in the phase I/II CHF6297 FIH trial in Chronic obstructive pulmonary disease in United Kingdom (Inhalation) (NCT02815488)
  • 19 May 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Lung disorders presented at the 113th International Conference of the American Thoracic Society (ATS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top